Extracellular vesicles (EVs) are tiny particles shed by cells that carry important molecular “clues” about the cell’s identity and condition.
Euan Ashley’s lab explores the intricate interactions of gene variants. Tiny “typos,” or genetic mutations, can sneak into segments of DNA. Many of these are harmless, but some can cause health problems. Two or more genes can team up and change the outcome of a physical or molecular trait. This phenomenon, known as epistasis, occurs through complex interactions between genes that are functionally related—such as those that support protein creation.
An Italian study published in Nature Medicine provides compelling evidence that fecal microbiota transplantation (FMT) can enhance the effectiveness of immunotherapy in patients with advanced metastatic renal cell carcinoma (mRCC).
University of British Columbia researchers have engineered gut bacteria that dim their fluorescent glow in the presence of illness. Their findings could improve how we diagnose problems in the gut by using bacteria that already live there. The work appears in Cell.
A Japanese research team has discovered a new compound that can advance the body’s internal clock—offering hope for faster recovery from jet lag and better adaptation to night-shift work.
Baylor College of Medicine researchers are part of a collaborative research group with AstraZeneca and Memorial Sloan Kettering Cancer Center that have identified 22 genes which increase the risk of developing a range of chronic conditions following a common viral infection.
New research reveals how Parkinson’s spreads from the gut to the brain, with the help of immune cells—offering a new potential therapeutic strategy—in a study in mice led by scientists at the UK Dementia Research Institute at UCL (University College London).
Fecal microbiota transplants (FMT) can dramatically improve cancer treatment, suggest two groundbreaking studies published in the Nature Medicine journal.
A new nano-sized drug carrier that finds bone tumors and releases treatment exactly where it’s needed is here to improve the precision and comfort of cancer therapy.
Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR system.